ImmunoSensation2 participates in research network CANTARApril 14, 2022
CANTAR (CANcer TARgeting) research network funded with 19.4 million euros
The new research network CANTAR (CANcer TARgeting) in the field of oncology aims to develop new chemical substances to identify specific driving pathways of cancer and to explore how cancer can "escape" the immune system. The lead partner is the University of Cologne, with Humboldt Professor Dr. Henning Walczak of the Center for Biochemistry as designated spokesperson. Cluster Member Prof. Dr. Michael Hölzel, director of the Institute for Experimental Oncology at the University Hospital Bonn, is involved. CANTAR is funded with a total of 19.4 million euros for the funding period.
The network bundles highly complementary knowledge available in NRW and builds on already established collaborations among the partners. It pursues a holistic approach in which researchers from chemistry, biology and medicine work together in a way that is unique in Europe. The focus is on the discovery and development of substances that act specifically on cancer cells and spare normal tissue. In addition, active substances are being developed that intervene in cancer-specific metabolic processes or make tumor cells more visible to the patient's own immune system. CANTAR bridges the gap between basic research and translational clinical cancer research.
The University of Duisburg-Essen, TU Dortmund University, the Universities of Bonn and Düsseldorf, RWTH Aachen University, the German Center for Neurodegenerative Diseases in Bonn and the Max Planck Institute of Molecular Physiology in Dortmund are involved as co-applicants.
Prof. Michael Hölzel
Institute of Experimental Oncology
Medical Faculty, University of Bonn
University Hospital of Bonn